Wang Yinxiang Talks About KRAS: The Applause at ASCO Is Only the Beginning of the Long Run

▤ Summary

This article profiles JACOBIO founder Wang Yinxiang and traces the company’s work on SHP2 and KRAS drug development. It explains how early scientific validation, clinical data, and licensing deals shifted the company from an immune-therapy hypothesis toward KRAS-focused programs. It also highlights the competitive split between small-molecule pan-KRAS approaches and Revolution Medicines’ pan-RAS molecular-glue strategy. The piece emphasizes the commercial pressure points around partnerships, cash preservation, clinical milestones, and the race to prove first-in-class value. It ends by framing KRAS as an ongoing long-term competition across science, clinical execution, patent strategy, and commercialization.

▦ Linked Companies